Adnkronos (Adnkronos) – "The new Consolidated Pharmaceutical Legislation Act should bring about the important and substantial change of bringing healthcare closer to citizens. This is the first aspect that, evidently, concerns everyone." This was stated by Ugo Cappellacci (FI), president of the XII Social Affairs Committee of the Chamber of Deputies, speaking at the event "The Future of Pharmaceutical Legislation: A Systemic Vision," organized by Nuove Reti in Rome.
"Then there is the aspect concerning the pharmaceutical industry," he emphasized, "which could allow it to work toward its goals, also encouraging greater investment, without falling into the jungle of bureaucratic procedures, through simplification at the regional level.
Furthermore, the new Consolidated Law brings order to a legislation that is currently very fragmented, which has accumulated over time and is in need of revision."
According to Cappellacci, among the many aspects impacted by the Consolidated Law, "some are more important than others. I believe the most important aspect is facilitating treatment for citizens by accelerating the process, making a drug more readily accessible, and, at the same time, incentivizing the industry to invest in that drug.
Today, especially in the international context, difficulties arise when territories are unable to valorize their contribution in terms of investments, not only for production but also for research" he concluded.
News
webinfo@adnkronos.com (Web Info)